Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2012 - 2026)

Ptc Therapeutics' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 113.45% year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $47.0 million, a 71.0% increase from a year earlier, with the FY2025 full-year figure at $38.8 million, down 48.7% from the prior year.
• Depreciation & Amortization (CF) advanced to $15.4 million in Q1 2026 per PTCT's latest filing, from $12.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $80.7 million in Q4 2023 and bottomed at $6.5 million in Q3 2024.
• The 5-year median for Depreciation & Amortization (CF) is $26.3 million (2022), against an average of $29.1 million.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 91.62% in 2024 and surged 113.45% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $38.9 million in 2022, then jumped by 107.65% to $80.7 million in 2023, then tumbled by 91.62% to $6.8 million in 2024, then jumped by 90.75% to $12.9 million in 2025, then rose by 19.46% to $15.4 million in 2026.
• Per Business Quant, the three latest PTCT Depreciation & Amortization (CF) figures stand at $15.4 million (Q1 2026), $12.9 million (Q4 2025), and $11.1 million (Q3 2025).